Madrigal's blockbuster drug gaining FDA approval this March has opened the doors to a wave of therapeutics from Eli Lilly, Boehringer Ingelheim,...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - MOUNTAINTODAY.IN - A La Une - 11/Jul 15:12
Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene
DelveInsight’s, “Neuroendocrine Tumors Pipeline Insight 2024” report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
Articles similaires
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, Clinical trials, Iron Deficiency Anemia prevalence, Treatment Algorithms | Akebia Therapeutics, Shield Therapeutics
mountaintoday.in - 04/Sep 08:17
Iron Deficiency Anemia Market As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the...
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, Clinical trials, Iron Deficiency Anemia prevalence, Treatment Algorithms | Akebia Therapeutics, Shield Therapeutics
mountaintoday.in - 04/Sep 08:17
Iron Deficiency Anemia Market As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the...
Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics
mountaintoday.in - 04/Sep 07:57
Interstitial Cystitis market The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)....
Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics
mountaintoday.in - 04/Sep 07:57
Interstitial Cystitis market The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)....
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
zacks.com - 29/Aug 09:15
Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.
Deucrictibant clinical, real-World, nonclinical, and discovery data to be presented at the Bradykinin Symposium
haei.org - 28/Aug 17:26
Deucrictibant clinical, real-World, nonclinical, and discovery data to be presented at the Bradykinin Symposium Pharvaris announced the acceptance of...
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
zacks.com - 28/Aug 15:49
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
TALTZ (ixekizumab) injection, solution [Eli Lilly and Company]
nlm.nih.gov - 29/Aug 04:00
Updated Date: Thu, 29 Aug 2024 00:00:00 EDT
Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?
zacks.com - 05/Sep 15:14
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.
Les derniers communiqués
-
Aucun élément